Publications-Periodical Articles

Article View/Open

Publication Export

Google ScholarTM

NCCU Library

Citation Infomation

Related Publications in TAIR

TitlePharmacokinetic and Pharmacodynamic Characterization of QT Prolonging Drugs Associated with Torsades de Pointes
Creator陳桂恒
Lin, Yeong-Liang ; Chan, Keith
Contributor智財所
Key WordsPharmacokinetic ; Pharmacodynamic ; QT prolongation ; Torsades de Pointes
Date2008-05
Date Issued7-Mar-2014 17:29:51 (UTC+8)
SummaryQT-prolonging drugs are occasionally associated with Torsades de Pointes (TdP). In this study, we compared the pharmacokinetic and pharmacodynamic characteristics of QT-prolonging drugs associated with TdP and those not associated with TdP. The characteristics included the enzyme responsible for QT-prolonging drug metabolism; the change in drug exposure resulting from enzyme inhibition; the elimination half-life; the volume of distribution, bioavailability and protein binding; the increase in QT interval caused by the drug; and the increase in QT interval in the presence of metabolic inhibition. The results demonstrated that 9 of the 20 selected drugs were metabolized through CYP 3A4 alone and, among them, 4 were torsadogens. In the presence of metabolic inhibition, the increases in maximum plasma concentration (Cmax) of torsadogens were not greater those of nontorsadogens. The increases in AUC, elimination half-lives, volumes of distribution, bioavailability, and protein binding were comparable between the two groups. Almost all torsadogens caused an increase in QT interval greater than 10 msec. In contrast, only one nontorsadogen did. With concomitant administration of enzyme inhibitors, torsadogens caused an increase in QT interval ranging between 30 msec and 82 msec, while those of nontorsadogens were up to a maximum of 16 msec. In conclusion, drugs metabolized through CYP 3A4 alone are not necessarily more likely to be proarrhythmic. The increases in QT interval induced by the torsadogens are slightly greater than those of nontorsadogens. With metabolic inhibition, they are associated with significantly greater increases in QT interval.
RelationDrug Info. Journal, 42(3), 211-219
Typearticle
dc.contributor 智財所en_US
dc.creator (作者) 陳桂恒zh_TW
dc.creator (作者) Lin, Yeong-Liang ; Chan, Keithen_US
dc.date (日期) 2008-05en_US
dc.date.accessioned 7-Mar-2014 17:29:51 (UTC+8)-
dc.date.available 7-Mar-2014 17:29:51 (UTC+8)-
dc.date.issued (上傳時間) 7-Mar-2014 17:29:51 (UTC+8)-
dc.identifier.uri (URI) http://nccur.lib.nccu.edu.tw/handle/140.119/64516-
dc.description.abstract (摘要) QT-prolonging drugs are occasionally associated with Torsades de Pointes (TdP). In this study, we compared the pharmacokinetic and pharmacodynamic characteristics of QT-prolonging drugs associated with TdP and those not associated with TdP. The characteristics included the enzyme responsible for QT-prolonging drug metabolism; the change in drug exposure resulting from enzyme inhibition; the elimination half-life; the volume of distribution, bioavailability and protein binding; the increase in QT interval caused by the drug; and the increase in QT interval in the presence of metabolic inhibition. The results demonstrated that 9 of the 20 selected drugs were metabolized through CYP 3A4 alone and, among them, 4 were torsadogens. In the presence of metabolic inhibition, the increases in maximum plasma concentration (Cmax) of torsadogens were not greater those of nontorsadogens. The increases in AUC, elimination half-lives, volumes of distribution, bioavailability, and protein binding were comparable between the two groups. Almost all torsadogens caused an increase in QT interval greater than 10 msec. In contrast, only one nontorsadogen did. With concomitant administration of enzyme inhibitors, torsadogens caused an increase in QT interval ranging between 30 msec and 82 msec, while those of nontorsadogens were up to a maximum of 16 msec. In conclusion, drugs metabolized through CYP 3A4 alone are not necessarily more likely to be proarrhythmic. The increases in QT interval induced by the torsadogens are slightly greater than those of nontorsadogens. With metabolic inhibition, they are associated with significantly greater increases in QT interval.en_US
dc.format.extent 10317993 bytes-
dc.format.mimetype application/pdf-
dc.language.iso en_US-
dc.relation (關聯) Drug Info. Journal, 42(3), 211-219en_US
dc.subject (關鍵詞) Pharmacokinetic ; Pharmacodynamic ; QT prolongation ; Torsades de Pointesen_US
dc.title (題名) Pharmacokinetic and Pharmacodynamic Characterization of QT Prolonging Drugs Associated with Torsades de Pointesen_US
dc.type (資料類型) articleen